Table 3.

Summary of key secondary outcome measures.

Functional outcomes	n	Baselinea	120 days follow-upa	Difference	95% CI	P-value
UWS FR, mL/minute	10	0.13 ± 0.02	0.18 ± 0.02	0.06	0.03 to 0.09	.0009
UWS FR, % change from baseline	10	0 ± 12.4	50.2 ± 12.4	50.2	23.97 to 76.44	.0005
SWS FR, mL/minute	10	0.66 ± 0.11	0.75 ± 0.1	0.09	0.02 to 0.16	.017
SWS FR, % change from baseline	10	0 ± 6.5	20.2 ± 6.5	20.2	5.14 to 35.22	.0099
XQ summary score (0-100)	10	53.5 ± 6.7	30.9 ± 6.7	−22.6	−33.57 to −11.68	.0004
EORTC QLQ-H&N35 (scores 0-100)
HNDR	10	73.3 ± 7.2	46.7 ± 7.2	−26.7	−46.93 to −6.41	.013
HNSS	10	46.7 ± 8.3	23.3 ± 8.3	−23.3	−41.52 to −5.15	.015
HNSW	10	26.7 ± 4.8	16.7 ± 4.8	−10.0	−17.87 to −2.12	.016
Scintigraphic uptake score (scores 0-4)
All glands	10	1.7 ± 0.2	1.8 ± 0.2	0.1	−0.06 to 0.16	.34
PG	10	2.3 ± 0.2	2.4 ± 0.2	0.1	−0.06 to 0.16	.34
SMG	10	0.9 ± 0.2	0.9 ± 0.2	−0.1	−0.16 to 0.06	.34
Scintigraphic excretion fraction, %
All glands	10	53.3 ± 4.8	55.3 ± 4.8	2.0	−4.75 to 8.76	.52
PG	10	59.3 ± 6.0	60.8 ± 6.0	1.4	−6.85 to 9.94	.70
SMG	10	40.3 ± 5.0	44.3 ± 5.0	4.0	−4.16 to 12.06	.28
Saliva composition, mmol/L
UWS chloride	8	21.7 ± 2.3	19.0 ± 2.4	−2.68	−7.46 to 2.09	.23
SWS chloride	9	26.5 ± 3.4	25.9 ± 3.4	−0.61	−3.41 to 2.18	.63
UWS phosphate	8	4.7 ± 0.4	4.4 ± 0.4	−0.28	−1.44 to 0.88	.55
SWS phosphate	9	3.8 ± 0.2	3.6 ± 0.2	−0.22	−0.88 to 0.44	.47
UWS potassium	8	19.1 ± 1.4	18.2 ± 1.6	−0.91	−4.57 to 2.74	.54
SWS potassium	9	19.4 ± 1.1	19.4 ± 1.2	0.02	−2.85 to 2.81	.99
UWS sodium	8	8.4 ± 1.4	7.2 ± 1.5	−1.17	−3.80 to 1.46	.32
SWS sodium	9	14.7 ± 3.3	15.7 ± 3.4	1.02	−3.57 to 5.62	.62

Values are least squares means and standard errors, unless otherwise stated.